311 completed. 311 Phase 2, 59 Phase 1, 34 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 311 | Completed 311 |
| Phase 1 | 59 | Completed 59 |
| Phase 3 | 34 | Completed 34 |
Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. AZD2389 - Liver Fibrosis, Hepatic Cirrhosis | Phase 2 | Completed | AstraZeneca | 40 | 2024-12-06 | 2026-07-06 |
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 213 | 2024-11-15 | 2026-11-17 |
| Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems Lemborexant, Placebo - Cirrhosis, Liver Cirrhosis | Phase 2 | Completed | Universitas Indonesia | 82 | 2024-10-01 | 2026-03-18 |
| Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment Mesenchymal Stem Cells from Wharton´s jelly - Systemic Sclerosis Pulmonary, Pulmonary Hypertension | Phase 1 / Phase 2 | Completed | Fundación Neumologica Colombiana | 1 | 2024-05-15 | 2026-04-21 |
| A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) Foscenvivint - Liver Cirrhosis | Phase 2 | Completed | Kiminori Kimura, MD | 5 | 2024-05-08 | 2026-05-01 |
| A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin - Liver Cirrhosis | Phase 2 | Completed | AstraZeneca | 73 | 2024-02-15 | 2026-01-20 |
| Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. K-808 (Dose A), K-808 (Dose B), Placebo - Primary Biliary Cholangitis | Phase 2 | Completed | Kowa Research Institute, Inc. | 46 | 2024-02-07 | 2026-10-07 |
| Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 30 | 2023-07-05 | 2026-04-15 |
| Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) INS018_055, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Completed | InSilico Medicine Hong Kong Limited | 71 | 2023-06-19 | 2025-12-11 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Intralesional Metformin Versus Triamcinolone for Keloid Treatment Intralesional Metformin, Intralesional Triamcinolone Acetonide - Keloids | Phase 2 | Completed | Al-Azhar University | 30 | 2023-05-06 | 2026-11-06 |
| A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction golexanolone, Placebo - Primary Biliary Cholangitis (PBC) | Phase 1 / Phase 2 | Completed | Umecrine Cognition AB | 207 | 2023-04-14 | 2026-10-16 |
| A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis AZD2693, Placebo - Nonalcoholic Steatohepatitis | Phase 2 | Completed | AstraZeneca | 220 | 2023-03-15 | 2026-10-28 |
| Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids Dupilumab - Keloid | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 20 | 2023-01-13 | 2026-09-18 |
| A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer IOA-289 - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | iOnctura | 16 | 2022-10-10 | 2026-03-30 |
| Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis EP547, Placebo - Pruritus | Phase 2 | Completed | Escient Pharmaceuticals, Inc | 62 | 2022-10-06 | 2025-07-31 |
| REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study Sirolimus 0.5Mg Tab, 1st MRI scan, 1st Percutaneous or Endoscopic Ultrasound guided liver biopsy - Advanced Chronic Liver Disease | Phase 2 | Completed | Nottingham University Hospitals NHS Trust | 41 | 2022-07-25 | 2024-10-01 |
| A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis Cotadutide, Placebo - Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | Phase 2 | Completed | AstraZeneca | 54 | 2022-07-14 | 2025-09-03 |
| Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients Nefopam, Placebo (Vehicle) - Burn; Multiple Body Regions, Max. Second Degree, Third-Degree Burn | Phase 2 | Completed | University of Alberta | 50 | 2022-07-10 | 2026-07-24 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar AK3280 Cream, Placebo cream - Hypertrophic Scar | Phase 1 / Phase 2 | Completed | Shanghai Ark Biopharmaceutical Co., Ltd. | 30 | 2022-07-08 | 2026-06-22 |
Showing 20 of 311. Sign in to see all of them.
Liver Cirrhosis (75) · Cicatrix (45) · Pulmonary Fibrosis (36) · Liver Cirrhosis, Biliary (33) · Non-alcoholic Fatty Liver Disease (26) · Hepatitis C (21) · Hypertension, Portal (18) · Keloid (18) · Idiopathic Pulmonary Fibrosis (17) · Ascites (14) · Hepatic Encephalopathy (13) · Cicatrix, Hypertrophic (12) · Fatty Liver (11) · Liver Diseases (11)
Pathological Conditions, Signs and Symptoms (311) · Pathologic Processes (307) · Digestive System Diseases (167) · Liver Diseases (155) · Liver Cirrhosis (36) · Respiratory Tract Diseases (35) · Skin and Connective Tissue Diseases (35) · Bile Duct Diseases (34) · Biliary Tract Diseases (33) · Cholestasis, Intrahepatic (32) · Infections (32) · Lung Diseases (32) · RNA Virus Infections (32) · Virus Diseases (32)
TGFB3 protein, human (14) · pirfenidone (10) · Ribavirin (6) · Rituximab (6) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (5) · Saline Solution (5) · Transforming Growth Factor beta3 (5) · Albumins (4) · Diet (4) · Exercise (4) · Sodium Chloride (4) · Terlipressin (4) · simtuzumab (4) · Allopurinol (3) · Botulinum Toxins, Type A (3)
Renovo (17) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (13) · Gilead Sciences (10) · Pfizer (6) · Hospital Clinic of Barcelona (5) · University of Alberta (5) · AstraZeneca (4) · Boehringer Ingelheim (4) · Bristol-Myers Squibb (4) · Conatus Pharmaceuticals Inc. (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · Novartis Pharmaceuticals (4) · Post Graduate Institute of Medical Education and Research, Chandigarh (4) · Assistance Publique - Hôpitaux de Paris (3) · Capstone Therapeutics (3)
United States (155) · United Kingdom (53) · Canada (45) · Germany (41) · Spain (40) · Italy (34) · France (33) · Belgium (24) · China (22) · Australia (21) · Japan (14) · Argentina (13) · Czechia (13) · Netherlands (13) · South Korea (11)
Jonathan Duncan (5) · James Bush (3) · David Hagerty, MD (2) · Hossein Baharvand, PhD (2) · Jaime Bosch, MD (2) · James Bush, MBChB (2)
PMID 19362676, PMID 28993537, PMID 33657443, PMID 38780109, PMID 39115183, PMID 10077078, PMID 11242330, PMID 11348456, PMID 12845617, PMID 15316341, PMID 16442954, PMID 16544259, PMID 16651948, PMID 16734808, PMID 16901024, PMID 16987047, PMID 17147494, PMID 17206944, PMID 17356110, PMID 17721093, PMID 17903050, PMID 18068515, PMID 18184077, PMID 18346996, PMID 18508290, PMID 18534768, PMID 18555763, PMID 18580208, PMID 18669816, PMID 18843115, PMID 18945255, PMID 19215252, PMID 19289689, PMID 19341651, PMID 19357910, PMID 19594300, PMID 19797971, PMID 19802513, PMID 19877169, PMID 19898214, PMID 20007927, PMID 20009818, PMID 20012639, PMID 20440184, PMID 20506355, PMID 20541828, PMID 20677940, PMID 20684729, PMID 20739168, PMID 20953964
2016 (8), 2004 (2), 2005 (2), 2009 (2), 2015 (2), 2017 (2), 2019 (2), 2023 (2), K01HL096434 (1), N01CN00035 (1), N01CN00042 (1), P30CA015083 (1), P30CA060553 (1), P30CA124435 (1), P50HL067665 (1)